• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

骨髓增生异常综合征患者的血管生成和生存。

Angiogenesis and survival in patients with myelodysplastic syndrome.

机构信息

Clinic of Hematology, Clinical Center of Vojvodina, Faculty of Medicine, Hajduk Veljkova 1-3, 21000 Novi Sad, Serbia.

出版信息

Pathol Oncol Res. 2012 Jul;18(3):681-90. doi: 10.1007/s12253-012-9495-y. Epub 2012 Jan 24.

DOI:10.1007/s12253-012-9495-y
PMID:22270865
Abstract

Angiogenesis has been implicated in the pathogenesis and prognosis of myelodysplastic syndrome (MDS). In this study, we investigated the relationship between microvessel density (MVD), vascular endothelial growth factor (VEGF) expression, common morphological and clinical factors, and survival in patients with MDS. We examined the MVD of paraffin-embedded bone marrow sections from 70 MDS patients and 31 controls. VEGF expression was determined in 50 patients and 20 controls. The median MVD in MDS patients was significantly higher than that in controls (p = 0.025), whereas there was no difference in VEGF expression between MDS patients and controls. In univariate analysis, increased MVD was associated with a shorter survival time (p = 0.023). However, in multivariate analysis, MVD was not an independent predictor of survival. The VEGF expression did not influence survival in univariate analysis. Survival was independently influenced by platelet count (p = 0.0073), cytogenetic risk category (p = 0.022), and transfusion dependence (p = 0.0073). Neither MVD nor VEGF expression were predictors for progression to acute myeloid leukemia in univariate analysis. Progression to acute myeloid leukemia was independently influenced only by the cytogenetic risk category (p = 0.022). This study confirmed increased MVD in MDS. It does not support an independent prognostic role of angiogenesis in MDS.

摘要

血管生成与骨髓增生异常综合征(MDS)的发病机制和预后有关。在这项研究中,我们研究了微血管密度(MVD)、血管内皮生长因子(VEGF)表达、常见形态学和临床因素与 MDS 患者生存之间的关系。我们检测了 70 例 MDS 患者和 31 例对照者石蜡包埋骨髓切片的 MVD。在 50 例患者和 20 例对照者中测定了 VEGF 表达。MDS 患者的中位 MVD 明显高于对照组(p=0.025),而 MDS 患者和对照组之间的 VEGF 表达没有差异。单因素分析显示,MVD 增加与生存时间缩短相关(p=0.023)。然而,多因素分析显示,MVD 不是生存的独立预测因素。VEGF 表达在单因素分析中对生存没有影响。在单因素分析中,血小板计数(p=0.0073)、细胞遗传学危险分类(p=0.022)和输血依赖(p=0.0073)对生存有独立影响。在单因素分析中,MVD 和 VEGF 表达都不是向急性髓系白血病进展的预测因素。向急性髓系白血病进展仅受细胞遗传学危险分类的独立影响(p=0.022)。这项研究证实 MDS 中存在 MVD 增加。它不支持血管生成在 MDS 中具有独立的预后作用。

相似文献

1
Angiogenesis and survival in patients with myelodysplastic syndrome.骨髓增生异常综合征患者的血管生成和生存。
Pathol Oncol Res. 2012 Jul;18(3):681-90. doi: 10.1007/s12253-012-9495-y. Epub 2012 Jan 24.
2
Biomarkers of angiogenesis as prognostic factors in myelodysplastic syndrome patients treated with hypomethylating agents.血管生成生物标志物作为接受去甲基化药物治疗的骨髓增生异常综合征患者的预后因素
Leuk Res. 2016 Nov;50:21-28. doi: 10.1016/j.leukres.2016.08.012. Epub 2016 Sep 5.
3
Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.骨髓增生异常综合征患者骨髓活检中肿瘤坏死因子-α的过表达:与贫血及预后的关系
Eur J Haematol. 2005 Dec;75(6):485-91. doi: 10.1111/j.1600-0609.2005.00551.x.
4
[Angiogenesis in bone marrow of myelodysplastic syndrome patients].[骨髓增生异常综合征患者骨髓中的血管生成]
Pol Arch Med Wewn. 2007 Apr;117(4):25-30.
5
[A preliminary observation of bone marrow angiogenesis in patients with myelodysplastic syndromes].[骨髓增生异常综合征患者骨髓血管生成的初步观察]
Sichuan Da Xue Xue Bao Yi Xue Ban. 2005 Jan;36(1):69-71.
6
Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes.骨髓增生异常综合征中血管生成与临床分期、细胞凋亡及预后评分的关系
Leuk Res. 2006 Mar;30(3):247-53. doi: 10.1016/j.leukres.2005.07.003. Epub 2005 Aug 15.
7
High bone marrow angiopoietin-1 expression is an independent poor prognostic factor for survival in patients with myelodysplastic syndromes.高骨髓血管生成素-1 表达是骨髓增生异常综合征患者生存的独立不良预后因素。
Br J Cancer. 2011 Sep 27;105(7):975-82. doi: 10.1038/bjc.2011.340. Epub 2011 Aug 30.
8
Increased angiogenesis in chronic idiopathic myelofibrosis: vascular endothelial growth factor as a prominent angiogenic factor.慢性特发性骨髓纤维化中血管生成增加:血管内皮生长因子作为一种主要的血管生成因子。
Hum Pathol. 2007 Jul;38(7):1057-1064. doi: 10.1016/j.humpath.2006.12.011. Epub 2007 Apr 18.
9
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.骨髓增生异常综合征患者骨髓中血管内皮生长因子(VEGF)的免疫组织化学检测:VEGF表达与FAB分型之间的相关性
Leuk Lymphoma. 2006 Mar;47(3):451-60. doi: 10.1080/10428190500353083.
10
Prognostic evaluation of the microvascular network in myelodysplastic syndromes.骨髓增生异常综合征微血管网络的预后评估
Leukemia. 2001 Sep;15(9):1369-76. doi: 10.1038/sj.leu.2402220.

引用本文的文献

1
The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.间充质基质细胞在骨髓增生异常综合征患者中的免疫作用。
Front Immunol. 2022 Dec 7;13:1078421. doi: 10.3389/fimmu.2022.1078421. eCollection 2022.
2
Immune Dysfunction, Cytokine Disruption, and Stromal Changes in Myelodysplastic Syndrome: A Review.骨髓增生异常综合征中的免疫功能障碍、细胞因子紊乱和基质改变:综述。
Cells. 2022 Feb 8;11(3):580. doi: 10.3390/cells11030580.
3
The Dynamic Interface Between the Bone Marrow Vascular Niche and Hematopoietic Stem Cells in Myeloid Malignancy.

本文引用的文献

1
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?骨髓增生异常综合征的抗血管生成治疗:是否有作用?
Curr Hematol Malig Rep. 2008 Jan;3(1):10-8. doi: 10.1007/s11899-008-0003-0.
2
Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q.来那度胺用于除5q缺失外其他核型的输血依赖型、低危和中危-1型骨髓增生异常综合征的2期研究。
Blood. 2008 Jan 1;111(1):86-93. doi: 10.1182/blood-2007-01-068833. Epub 2007 Sep 24.
3
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes.
骨髓血管龛与髓系恶性肿瘤中造血干细胞之间的动态界面
Front Cell Dev Biol. 2021 Mar 11;9:635189. doi: 10.3389/fcell.2021.635189. eCollection 2021.
4
Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes.燃烧和煽动:骨髓增生异常综合征中炎症影响的光谱。
Blood Rev. 2019 Jul;36:57-69. doi: 10.1016/j.blre.2019.04.004. Epub 2019 Apr 18.
5
Histopathology in the diagnosis of high-risk myelodysplastic syndromes.组织病理学在高危骨髓增生异常综合征诊断中的应用
J Clin Exp Hematop. 2018;58(2):51-60. doi: 10.3960/jslrt.18009.
6
Signal transduction inhibitors in treatment of myelodysplastic syndromes.信号转导抑制剂在骨髓增生异常综合征治疗中的应用。
J Hematol Oncol. 2013 Jul 10;6:50. doi: 10.1186/1756-8722-6-50.
用于预测骨髓增生异常综合征患者生存及白血病演变的时间依赖性预后评分系统。
J Clin Oncol. 2007 Aug 10;25(23):3503-10. doi: 10.1200/JCO.2006.08.5696.
4
Diagnostic value of histology and immunohistochemistry in myelodysplastic syndromes.组织学和免疫组化在骨髓增生异常综合征中的诊断价值
Leuk Res. 2007 Dec;31(12):1609-16. doi: 10.1016/j.leukres.2007.05.010. Epub 2007 Jul 2.
5
Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia.骨髓增生异常综合征转化为明显白血病过程中骨髓血管生成的调控
Br J Haematol. 2007 May;137(3):206-15. doi: 10.1111/j.1365-2141.2007.06539.x.
6
Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference.骨髓增生异常综合征诊断与治疗的定义及标准:工作会议的共识声明与报告
Leuk Res. 2007 Jun;31(6):727-36. doi: 10.1016/j.leukres.2006.11.009. Epub 2007 Jan 25.
7
Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion.来那度胺治疗伴有5号染色体长臂缺失的骨髓增生异常综合征
N Engl J Med. 2006 Oct 5;355(14):1456-65. doi: 10.1056/NEJMoa061292.
8
Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.骨髓增生异常综合征患者骨髓中血管内皮生长因子(VEGF)的免疫组织化学检测:VEGF表达与FAB分型之间的相关性
Leuk Lymphoma. 2006 Mar;47(3):451-60. doi: 10.1080/10428190500353083.
9
The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).抗血管生成药物AG-013736在预后较差的老年急性髓系白血病(AML)或骨髓增生异常综合征(MDS)患者中活性极小。
Leuk Res. 2006 Jul;30(7):801-11. doi: 10.1016/j.leukres.2005.10.024. Epub 2005 Dec 5.
10
Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS).通过将乳酸脱氢酶(LDH)纳入国际预后评分系统(IPSS)作为额外的预后变量来完善该系统,以改善原发性骨髓增生异常综合征(MDS)患者的风险评估。
Leukemia. 2005 Dec;19(12):2223-31. doi: 10.1038/sj.leu.2403963.